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1      Introduction
Cloned human embryos are cells (embryos) 
produced by implanting the nuclei of human 
somatic cells into enucleated eggs. By purpose 
of use, human cloning can be classified into 
“reproductive cloning,” which uses cloned 
embryos for producing cloned human individuals, 
and “therapeutic cloning,” in which cloned 
embryos are used for medical treatment and 
research purposes.
International opinion is against the production 
of cloned human individuals (reproductive 
cloning), represented by an international treaty 
banning human cloning discussed in the United 
Nations. Over this issue, the United Nations has 
split into (1) those appealing for a complete 
ban on human cloning and (2) those accepting 
therapeutic cloning, claiming that banning 
should be limited to the production of cloned 
human individuals and that regulating production 
and using cloned human embryos should be 
the decision of individual governments. The 
discussion started in 2001, but no agreement 
has been reached, and it will continue until this 
December (2004).
In October 2003, the Inter Academy Panel 
(IAP), an international science academy forum 
with membership of over 80 academies from 
around the world including the Science Council 
of Japan and the U.S. National Academy of 
Sciences has issued a statement on human cloning 
regulation. In this statement, IAP urges the 
United Nations to ban cloned human individual 
production (reproductive cloning) but also 
claim that “therapeutic cloning” intended to 
establish ES cells for research and therapeutic use 
should not be banned, considering its potential 
contribution to medical and scientific progress.
While the application of cloning technology 
to human beings has become a controversial 
issue in many areas, in March 2004, Korean and 
U.S. researchers successfully established ES cells 
from cloned human embryos and published the 
results of their research in the American journal, 
Science[1]. ES cells derived from cloned embryos 
had already been established in experimental 
animals, but the report demonstrates that they 
can also be established in humans. At the same 
time, the low success rate of the reported 
method, i.e., merely a single ES cell line could be 
obtained from 242 eggs, suggests that, in addition 
to ethical issues, there are a number of scientific 
and technical barr iers to overcome before 
applying similar methods in practice.
In Japan, the Bioethics Committee of the 
Council for Science and Technology Policy has 
been discussing whether or not to pave the way 
to the production and use of cloned human 
embryos (therapeutic cloning). This report 
overviews the status of cloned human embryos, 
both from a biological and a social point of view.
2      Laws and regulations
       concerning cloned
       human embryos
In Japan, any research concerning cloned 
hu m a n  e m br yo s  mu s t  b e  co ndu c t e d  i n  
compliance with the laws and regulations. 
Currently, governmental guidelines with de facto 
legal force prohibit research on the production 
and use of cloned human embryos. From an 
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international standpoint, some countries have 
laws concerning human cloning, while others do 
not, and some laws prohibit any human cloning 
at all, while others prohibit only reproductive 
cloning. In December 2000, Japan enacted 
the “Law concerning Regulation relating to 
Human Cloning Techniques and other Similar 
Techniques” (2000 law no. 146, hereafter referred 
to as the “Law concerning human cloning”), 
which legally prohibits the implantation of 
cloned human embryos into a uterus (prohibition 
of the creation of cloned human individuals) 
and imposes criminal charges (imprisonment 
of up to 10 years or a fine of up to 10 million 
yen) for any violation. Based on this law, the 
Minister of Education, Culture, Sports, Science 
and Technology has established “Guidelines on 
handling specified embryos” (hereafter referred 
to as the “Guidelines for specified embryos”) 
that instruct users to follow the guidelines when 
handling specif ied embryos such as cloned 
human embryos and chimeric or hybrid embryos 
(mixtures or hybrids between human and other 
animals) and impose substantial criminal charges 
for any violation. In other words, anyone whose 
research has been judged to violate the guidelines 
by the Minister and who does not follow the 
Minister’s improvement or suspension orders, 
etc., will face imprisonment of up to 1 year or a 
fine of up to 1 million yen.
Table 1 : Classification of specified embryos employed in laws and guidelines in Japan
Specified embryos (simplified forms of the definitions given in the Law concerning human cloning):
(1) Human somatic clone embryo : human enucleated unfertilized egg + human somatic nucleus
(2) Human-animal chimeric embryo : human embryo + animal embryo
(3) Human-animal amphimictic embryo : human gamete fertilized with an animal gamete (or a clone obtained using its nucleus)
(4) Human-animal hybrid embryo : animal enucleated unfertilized egg + human cell nucleus (including the embryo)
(5) Human split embryo : embryo produced by splitting the human early embryo (the developing embryo)
(6) Human-human chimeric embryo : human embryo + human cell (including the embryo)
(7) Human embryonic clone embryo : human enucleated unfertilized egg + human early embryo nucleus
(8) Animal-human hybrid embryo : human enucleated unfertilized egg + animal cell nucleus
(9) Animal-human chimeric embryo : animal embryo + human cell
Definitions of the terms used
Human : contains a human nucleus
Animal : contains an animal nucleus
Chimeric embryo : an embryo produced by mixing no fewer than two embryos. Chimaera embroyo
Amphimictic embryo :  a hybrid embryo produced through the fertilization of gametes, and a cloned embryo obtained using its 
nucleus
Hybrid embryo : an embryo produced by transplanting a nucleus into an enucleated egg or a fertilized egg
Figure 1 : Structure of regulations concerning human cloned embryos
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The Guidelines for specified embryos prohibit 
any production or use of specified embryos 
given in the list, except for the production of 
animal-human chimeric embryos. In other words, 
not only the implantation of cloned human 
embryos into uteruses but also their production is 
prohibited by the guidelines.
3      Significance
       of therapeutic cloning
The greatest value of therapeutic cloning 
is its potential to produce patients’ own cell 
transplants, thus avoiding the immunological 
rejection that occurs in regenerative medicine. 
T h i s  s e c t io n  s u m m a r i z e s  t he  s i t u a t io n  
surrounding this aspect of therapeutic cloning.
Regenerative medicine refers to technologies to 
regenerate functionally disturbed or incompetent 
tissues or organs through the active use of cells. 
Using various techniques, cells, tissues, etc., are 
artificially adapted to perform their intended 
functions and then implanted into dysfunctional 
organs or tissues so that their lost functions and 
health are restored.
In organ/tissue transplantation, immunological 
rejection occurs in individuals (recipients) whose 
cells, tissues, etc., have received implants. For 
successful results in regenerative medicine, 
this rejection must be adequately suppressed. 
Immunosuppressants are usually used, and the 
improvement in immunosuppressants (emergence 
of cyclosporin) has largely contributed to the 
establishment of the medical transplantation 
techniques used today for the heart, lungs, liver, 
kidneys and other organs.
The immunosuppressants used to prevent 
and suppress immunological rejection are 
accompanied by certain adverse effects listed 
in Table 2 (listing only drugs generally used in 
renal transplantation. Other immunosuppressants 
such  a s  a nt i l y mphoc y te  a nt ibod ie s  a nd  
anti - IL2 receptor antibodies are not shown). 
After transplantation, patients usually receive 
two or more kinds of immunosuppressant in 
combination and must continue taking them 
for rest of their lives (as long as they have the 
implants within them).
The results of an investigation conducted 
in 1983 show that one - year gra f t survival 
rates a f ter cadaver ic transplantation were 
72% and 52% when dosing with cyclosporin 
alone (117 cases) and dosing with other agents 
(steroids/azathioprine, 115 cases), respectively[5]. 
T he  g r a f t  s u r v i v a l  r a t e  a f t e r  c ad ave r ic  
transplantation has increased to 88.7% through 
combination therapy (calculated from 268 cases 
examined since 1983[6]).
As can be seen, eliminating immunological 
rejection is essential in medical transplantation 
as well as in the cell transplantation employed in 
regeneration medicine. Since rejection is due to 
variation in immune-related genes (differences 
in tissue antigens) observed among individuals, 
rejection is in theory suppressed by establishing 
ES cells derived from embryos (with the genomic 
genes of the patients) cloned from the patients 
themselves and by implanting cells appropriately 
differentiated from such ES cells.
In mice, the use of ES cells derived from cloned 
embryos has actually proved effective in avoiding 
rejection in regenerative medicine[7].
Table 2 : Immunosuppressants
Immunosuppressants Adverse effects
common to all agents reduced resistance to infectious diseases
cyclosporin
nephropathy, hepatopathy, encephalopathy symptoms, neuro-Behcet-like symptoms, acute pancreatitis, 
thrombotic microangiopathy, hemolytic anemia, rhabdomyolysis, lymphoma, lymphoproliferative tumor, 
malignant tumor, hirsutism, trembling of hands, etc.
tacrolimus nephropathy, diabetes, trembling of hands, cardiopathy, etc.
steroids peptic ulcer, diabetes, hypertension, glaucoma, cataract, obesity, moon face, etc.
mycophenolate mofetil leukopenia, anemia, diarrhea, inappetence, etc.
azathioprine leukopenia, inappetence, nausea, liver dysfunction, etc.
mizoribine leukopenia, liver dysfunction, inappetence, nausea, stomatitis, pancreatitis, etc.
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4      Status of cloning technology
This section overviews the technical aspects of 
the process of establishing ES cells from cloned 
embryos, from the perspective of applying cloned 
human embryos to regenerative medicine.
Cloned human embryo production involves 
techniques that take the nucleus of a somatic cell 
(containing genomic genes principally identical 
to the donor of the somatic cell) out of the 
target individual to be cloned, transfer it into an 
egg, and treat the egg appropriately to promote 
embryo development without the involvement of 
gametes (sperm and eggs) or fertilization. From 
the resulting early embryo (at the blastocyst 
stage), a specific group of cells (inner cell mass) 
is removed and used to establish ES cells. This 
is how ES cells are established from cloned 
human embryos. Achievements in bioresearch 
in this process are discussed in the following 
paragraphs.
To date, cloned individuals have been obtained 
in sheep, mice, cattle, goats, pigs, rabbits, cats, 
mules, horses and rats using cloning technology. 
Success in the production of cloned individuals 
depends on the type of abnormality observed, 
etc., and these are different among the above 
species. Mice in particular, which are generally 
used i n  an i ma l  exper i ment s ,  have g reat  
physiological differences from other mammals.
Phenotypic abnormalities are believed to 
be caused by (1) technical factors such as 
artificial handling that may damage the eggs, 
(2) genetic factors, such as abnormalities in the 
genomes of the somatic cells used for nuclear 
transplantation, or the genetic variation observed 
in the differentiation or the aging process or 
(3) non-genetic factors (epigenetic factors are 
explained later) concerning reprogramming (to 
obtain a condition suitable for development) or 
egg activation.
4-1    Abnormalities observed
         in cloned individuals
The scient i f ic and techn ica l  aspects of 
cloning technology have been developed by 
analyzing results obtained from experiments 
on the production of cloned individuals from 
cloned embryos using domestic or experimental 
an ima ls.  The f ind ings f rom these cloned 
animal production experiments should help us 
understand the nature of cloned human embryos 
used for therapeutic cloning.
(1)  In animal experiments, when embryos 
produced through cloning are implanted 
into the uterus, most early mouse embryos 
die immediately after their implantation, 
i.e., at the stage of placenta formation, 
whi le catt le and sheep embr yos stop 
developing in late pregnancy, resulting in a 
high percentage of stillborn and abnormal 
babies. Moreover, the size of the newborn 
babies and their placentas is unusually large, 
and this commonly observed independent 
of species. After birth, a wide range of 
abnormalities is observed in respiratory 
function, kidneys, liver, heart, brain, etc., 
and obesity, oncogenesis and short life are 
observed after growth.
(2)  The r isk of inducing abnormal traits 
partially depends on the type of donor 
cell (fibroblasts, ES cells, etc.) used for 
nuclear transplantation. With ES cell nuclei, 
cloned embryo production is 10 -20 times 
more efficient than production using other 
somatic cells.
(3)   Abnor ma l i t ie s  obser ved  i n  c loned  
individuals are considered to be induced 
by abnor ma l  reprogram mi ng or  egg 
inactivation, the use of abnormal donor 
cel ls or in vitro culture. For example, 
the efficiency of microfertilization can 
deteriorate due to technical factors, even in 
the absence of non-genetic abnormalities. 
However, in biological terms, epigenetic 
factors*1 such as genome imprinting, rather 
than technical damage or genetic factors, 
seem to be the main cause of abnormal 
cloned individuals.
(4)  Reprogramming is an epigenetic process 
required to achieve a state suitable for 
initiating embryo development. The process 
appears to have two stages, i.e., during the 
formation of the gametes (sperms or eggs) 
in the reproductive organs, and after the 
fertilized eggs and embryos have started 
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developing. Since the nuclei of cloned 
embryos skip the process of gametogenesis, 
t h e y  c a n n o t  a c h i e ve  a  co mp l e t e l y  
reprogrammed state (Figure 2).
Even in embr yos der ived through usual 
sexual intercourse, the absence of normal 
epigenetic reprogramming after fertilization 
results in abnormal development. For example, 
parthenogenesis of an egg results in the formation 
of teratoma, whi le an embryo with only a 
sperm- derived nucleus results in developing 
vesicular mole.
Furthermore, the epigenetic factors involved 
in gametogenesis include a mode of gene 
modification cal led imprinting (mechanism 
for regulating gene expression which leads 
to differential expression between paternal 
and maternal genes) and the modification of 
non-imprinted genes, and the factors involved 
after the initiation of development include 
X-inactivation and telomere length regulation. 
Cloned embryos undergo normal epigenetic 
processes after the initiation of development, i.e., 
X-inactivation and telomere length regulation.
(5)  Cells consisting of various organs in cloned 
individuals differ greatly from those found 
in individuals produced through ordinary 
reproduction in terms of the kinds of gene 
expressed, DNA methylation patterns, 
expression levels of various substances, etc.
4-2    Procurement of eggs
The biological signif icance of using eggs 
to prepare cloned embryos is their capability 
of reprogramming the transplanted nuclei. 
Reprogramming is required to modify the cells, 
which have once experienced differentiation and 
are functioning as somatic cells, so that they can 
form early embryos again (initiate development).
(1)  Eggs can be prov ided ( i)  by female 
volunteers or (ii) from eggs obtained for 
fertility treatment or through other medical 
procedures.
From the viewpoint of human r ights and 
gender issues, there is a great fear that females 
may be treated as a means of supplying egg 
materials for human cloning. In the United 
Nations, A fr ican countr ies have expressed 
their concerns about “poor women in African 
countries becoming exploited as egg factories.” 
Moreover, egg retrieval imposes physical risks 
such as the use of ovulation- inducing agents, 
anesthesia and surgical operation. For instance, 
ovulation- inducing agents may induce severe 
symptoms such as ovarian hyperstimulation 
syndrome.
Meanwhile, eggs may be obtained through 
medical procedures other than fertility treatment, 
such as from ovaries removed in surgery.
(2)  There is no established method for the 
cryopreservation of eggs. However, the use 
of frozen eggs has resulted in successful 
in vitro fertilization in a number of cases. 
Advances in cryopreservation technologies 
should enable the preservation of individual 
Figure 2 : Process involving epigenetic modification
26
S C I E N C E  &  T E C H N O L O G Y  T R E N D S
27
Q U A R T E R L Y  R E V I E W  N o . 1 3  /  O c t o b e r  2 0 0 4
eggs or of eggs as a part of the ovary tissues.
(3)  Alternatives to using eggs collected or 
provided from living bodies to reprogram 
the somatic nuclei of donors are currently 
being developed, such as the use of eggs 
differentiated from human ES cells or eggs 
derived from other species. In 2003, Hü
bner, et al. reported that egg cells could 
be differentiated from mouse ES cells[9]. 
This report suggests that, although less 
efficiently than egg cells derived from living 
bodies, a large number of egg cell - l ike 
cel ls can easi ly be obtained (from ES 
cells through only in vitro treatment) as 
a tool for reprogramming somatic nuclei 
and initiating the development of cloned 
embryos. This report implicates that cells 
required for medical cell transplantation can 
be supplied on an industrial basis.
(4)  In the future, the development of new 
techniques for the reprogramming process, 
such as the direct reprogramming of 
somatic cells, may eliminate the necessity 
of eggs der ived from l iving bodies to 
obtain rejection - free cel ls that inherit 
the immunological characteristics of the 
patients themselves. Unfortunately, much 
of the biological mechanism underlying 
the reprogramming process remains 
unexplained, even at the level of animal 
experiments.
4-3    Low success rate
With sufficient technical skill, ES cells can 
generally be established from blastocysts derived 
from fertilized embryos with a 100% success 
rate. In comparison, establishing ES cells from 
cloned human embryos has a low success rate. 
Hwang et al. collected 242 eggs from 16 females 
and used them for nuclear transplantation to 
achieve 30 blastocysts (12%). However, only one 
ES cell strain could be obtained, resulting in an 
extremely low success rate compared to the rate 
using fertilized embryos. The ultimate success 
rate was 0.4%, which is impractical considering 
the use of eggs derived from living bodies.
Nevertheless, their report is significant in that 
it demonstrates the possibility of establishing 
ES cel ls from cloned human embryos, and 
technical issues should be solved by future 
research and development. As discussed in the 
section on abnormalities observed in cloned 
individuals, cloned embryos skip the process of 
nuclear reprogramming in the gametogenesis 
process, and developing an alternative means 
to this natural process requires basic research 
using experimental animals. Currently, there is 
no clear vision concerning the development or 
the results of such basic research, and scientific 
and technical breakthroughs are awaited. 
Nevertheless, including the use of ES cell-derived 
eggs (or cells similar to these) in research, we 
must establish a system under which research 
involving cloned human embryo production can 
be conducted within an appropriate framework.
5       Status of regeneration
       medicine research using
       ES cells
To date, transplantation experiments with 
animals using cells differentiated from ES cells 
have been reported on hematopoietic cells, 
dopamine-producing nerve cells, motor cells and 
insulin -producing cells, which are applicable 
to hematopoietic diseases, Parkinson’s disease, 
spinal cord injury and diabetes, respectively. 
Among these reports, an experiment using 
i m mu nosuppressed m ice s i mu lt aneous ly  
succeeded in differentiating ES cells derived from 
cloned embryos and using them in gene therapy 
through genetic recombination. The success 
of this experiment is based on the potential of 
cloned embryos in regenerative medicine and the 
technical advantage of using ES cells in genetic 
recombination.
In Japan, the Institute for Frontier Medical 
Science of Kyoto University has established the 
3 human ES cell lines (KhES-1, 2 and 3) shown 
in Table 3 and has already begun distributing 
some of them (human ES cell project information 
disclosure website). Their nature as ES cells is 
currently being confirmed, such as whether they 
are capable of stable self-replication (the forms 
of cells and colonies), their pluripotency, normal 
chromosomes (karyotype) and the expression 
of markers for undifferentiation (ALP, SSEA-4, 
TRA-1-60/81, Oct-3/4, Rex-1, etc.). The nature 
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of ES cells is not fully understood, and therefore 
requires further research, e.g., to elucidate the 
molecular mechanism of self-replication.
In addition to the various abnormalities found 
at the level of the individual, animals derived 
from cloned embryos differ from normal at tissue 
level. This generates risks in the application 
of cloned embryos to regenerative medicine, 
i.e., the use of artificially generated (naturally 
non-existing) cloned embryos as cell transplants. 
These abnormalities are believed to depend on 
reprogramming, but as mentioned earlier, their 
mechanisms are not fully understood, even in 
experimental animals. Meanwhile, the difference 
between cloned embryos and normal cells may 
be significant in the process of ontogenesis, but 
as long as they retain the functions required 
for cell transplants to treat adults, their safety 
and benefits may not be considered as practical 
problems. Furthermore, ethical issues concerning 
the procurement of eggs may be solved by a new 
alternative means, such as the use of materials 
removed in surgical operations or eggs (or 
egg-like cells) prepared from ES cells as tools for 
reprogramming.
Based on these points, various patterns of 
ES cell establishment are shown in Figure 3. A 
number of attempts have been made to establish 
ES cells applicable to regenerative medicine, not 
only ES cells derived from fertilized or cloned 
embryos but also egg-like cells derived from ES 
cells or the application of cell fusion techniques. 
Moreover, the British scientific journal, Nature, 
has recently published a report[10] by Japanese 
and Korean researchers who generated eggs with 
a mutation in a gene (H19) potentially involved 
in epigenetic genome imprinting in mice, and 
who successfully initiated development without 
fertilization in individual reproductive mice. 
This study clearly demonstrates the involvement 
of epigenetic phenomena in reprogramming, 
and other studies are also being conducted to 
elucidate the reprogramming mechanism.
6      Somatic stem cells
       and ES cells
In contrast with ES cells, which are derived 
from cloned human embryos, somatic stem cells 
are obtained from the tissues of adult individuals. 
Although their biological properties differ from 
those of ES cells, somatic stem cells are also 
useful in regenerative medicine. Unlike human 
embryos or cloned human embryos, the use of 
somatic stem cells is free from ethical issues. Here 
are some important points concerning somatic 
stem cells compared with cells derived from 
Table 3 : Examples of human ES cell strains established








Source: Prepared by the author based on 
the NIH Stem Cell Registry that presents the 
number of human ES cell lines approved by 
U.S. NIH by August 2001
Japan  3
ES cell lines established in May and October 
2003 by the Institute for Frontier Medical 
Sciences of Kyoto University
Figure 3 : Process for producing ES cells, etc.
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cloned embryos or ES cells.
(1)  Unlike cells artificially derived from cloned 
embryos, immature ES cells or cells derived 
from such cells, somatic stem cells are 
originally part of the body and can therefore 
be assumed to be safer when returned to 
the same body in medical transplantation.
(2)  Somatic stem cells potentially have various 
differentiation potencies and practical 
uses, as demonstrated in an attempt to 
differentiate mouse bone-marrow cells into 
myocardial cells. Transplantation therapy 
against leukemia, etc., using cord blood 
cells is already equivalent to bone marrow 
transplantation in terms of the number of 
patients receiving this therapy (cord blood 
cell transplantation requires a long recovery 
period and has a high risk of bleeding and 
infection in adult recipients, but strategies 
to overcome these disadvantages, such as 
alleviating preoperative myelosuppression 
and using in vitro culture, have been 
discussed).
  Stem cells have l imited differentiation 
potency, but as an exception to this, Jiang 
et al. (2002) have reported the isolation of 
pluripotent somatic stem cells[11]. These 
stem cells have been isolated in mice, rats 
and humans, but their application has not 
yet been researched. Some reports doubt 
the pluripotency of somatic stem cells, 
and their potential for future application is 
unclear.
(3)  Compared to ES cells, somatic stem cells are 
difficult to collect and propagate (ES cells 
can be propagated and maintained without 
limit over a long period of time).
(4)  Some of the advantages of ES cells are that 
their genes can be modified, they can be 
supplied in large amounts with consistent 
quality, their sublines can be established, 
and their supply can be stabil ized and 
standardized. On the other hand, such 
advantages are unknown or are hardly 
observed in somatic stem cells.
Mamoru Ito et a l .,  Centra l  Inst itute for 
E xper i ment a l  A n i m a l s ,  h ave  deve loped  
i m m u n o s u p p r e s s e d  m i c e  ( N O G  m i c e :  
NOD/SCID/γ (gamma) Cnul l)  intended for 
studying the clinical application of somatic stem 
cells and ES cells. They are expected to serve as a 
means of examining in vivo regeneration, and the 
differentiation and the safety of cell transplants.
As mentioned above, somatic stem cells and 
ES cells each have different advantages and 
disadvantages. If collected from the individual 
to be treated, somatic stem cells require neither 
the use of fertilized embryos nor the preparation 
of cloned embryos. However, they seem to have 
limited capacity for differentiation, propagation 
and retrieval from living bodies. Therefore, 
research must be promoted for both cell types.
According to the “Surveys on the clinical 
application of somatic stem cel ls in Japan” 
conducted by the Health Sciences Counci l 
in 2002, 90, 3 and 16 facil ities were at the 
stages of research, pre - clinical research and 
clinical study, respectively (based on data from 
the references[3]). At least in these facilities, 
transplantation of the epidermis or bone, or 
transplantation therapy for vascular occlusion 
d iseases,  has a l ready been per formed on 
actual patients in clinical trials. Furthermore, a 
Japanese patient with a spinal cord injury has 
received spinal cord regenerative medicine using 
olfactory ensheathing cells in China. Establishing 
regulations and guidelines for regenerative 
medicine has become an urgent social issue for 
Japan.
7      Debates on therapeutic
       cloning
7-1    Debates in Japan
Article 2 in the Supplementary Provisions 
of the “Law concerning Regulation relating to 
Human Cloning Techniques and other Similar 
Techniques” (2000) states that “the Government 
shall, within three years of enforcement of this 
Law, take necessary measures in accordance 
with the results of its study and examination 
of the provisions under this law, based on the 
results of the examination by the Council for 
Science and Technology Policy concerning the 
method of handling of human fertilized embryos 
as the beginning of human life.” The deadline 
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is June 2004, and the Expert Panel on Bioethics 
of the Council for Science and Technology has 
announced an interim report, “On basic concepts 
concerning the handling of human embryos.” 
In response to comments by the public on the 
report, the committee is continuing discussion 
to reach a public decision on whether to permit 
therapeutic cloning and whether to pave the way 
to regenerative medicine research.
There are var ious arguments concerning 
therapeutic cloning. From the ethical viewpoint, 
arguments in favor of therapeutic cloning are 
based on medical, scientific and humane reasons. 
Meanwhile, those against therapeutic cloning are 
mostly based on religious and personal ethical 
convictions, or fear of scientific uncertainty, 
and some even claim that regenerative medicine 
itself is unnecessary or that the potential to 
increase exploitation of the human body is not 
acceptable. Complete agreement has not yet been 
reached through these arguments, and neither is 
it expected in the future. Therefore, we should 
return to the original purpose of achieving both 
respect of individual rights and public benefit. 
In other words, the government must establish a 
social system that approves the independence of 
individuals with various ethical values and that 
ensures social safety and peace of mind.
7-2    Trends in therapeutic cloning
         in the United Nations and other countries
As mentioned earlier, the United Nations has 
not reached an agreement between those in 
favor of and those against therapeutic cloning. 
Complete proh ibit ion of  human clon ing,  
suggested by Costa Rica, is supported by more 
than 50 countries including the United States, 
African countries, the Vatican, Spain and Italy, 
while prohibition of only reproductive cloning is 
supported by more than 20 countries including 
Belgium, Germany, France and Japan. The United 
States, which supports complete prohibition, 
imposes regulations on NIH concerning the 
use of funds, but does not have any federal law 
that directly regulates the handling of human 
embryos including human clones. In other 
words, the country has no federal regulation on 
privately funded human embryo research, so 
human embryo technology has been developed 
in the private sector. The President’s advisory 
council announced “Human Cloning and Human 
Dignity” concerning cloning, “Monitoring Stem 
Cell Research” concerning stem cell research and 
“Reproduction and Responsibility” concerning 
assisted reproduction technologies in July 2002, 
January 2004 and March 2004, respectively. 
In these reports, the Council only mentions 
the necessity of social debate, the fact that the 
Council has been divided over this issue, and 
that the bill prohibiting both reproductive and 
therapeutic cloning of human has passed the 
House but has not been approved in the Senate. 
Meanwhile, ES cell research has been supervised 
by NIH (encouraging studies using existing 
ES cells that have been registered) based on a 
presidential statement in 2001. At the individual 
state level, state laws concerning cloning vary 
greatly, but the law in Cal i fornia approves 
therapeutic cloning (production of cloned human 
embryos).
In “The Ethical Implications of Research 
Involving Human Embryos” and the “Commission 
S t a f f  Work i ng  Paper :  Repor t  on  Hu ma n 
Embryonic Stem Cell Research” in 2000 and 2003, 
respectively, the EU suggests establishing strict 
conditions on the production of human fertilized 
embryos for research purposes. However, the 
organization principal ly respects decisions 
made by individual governments concerning 
the production of human embryos for research 
purposes or therapeutic cloning. In 2001, the 
European Parliament rejected a bill prohibiting 
the contr ibution of public funds to human 
embryo research (CNN).
To  t he  au t hor ’s  k nowledge,  cou nt r ie s  
prohibiting the establishment of ES cells from 
human embryos are Norway, Austria (imported 
ES cel l s  a re under d i scuss ion),  Germany 
(imported ES cells are approved), France (under 
review), Spain (under review) and Ireland. 
Switzerland approves the establishment of ES 
cells but explicitly prohibits both reproductive 
and therapeutic cloning by law. On the other 
hand, in countries such as U.K., Belgium, South 
Korea, China, Israel, Luxembourg, Italy (under 
discussion) and Taiwan, therapeutic cloning is 
permitted either explicitly by law or substantially 
through freedom from legal restrictions. In 
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France, a revision of the Bioethics bill is currently 
under discussion in Parliament, and while moving 
toward an acceptance of research using human 
embryos for limited purposes, the Parliament is 
divided over therapeutic cloning. A public poll 
conducted in France revealed that 65% of people 
distinguish between reproductive and therapeutic 
cloning, while 31% make no distinction. The 
results also indicate that 45% are in favor of 
therapeutic cloning, while 20-30% are against it 
(the Science Generation Initiative). In Singapore, 
a bill that allows therapeutic cloning is currently 
under discussion and should be approved in the 
near future (ABC Online).
As in Japan, methods of handling of human 
embryos are controversial in many developed 
countries. Discussion concerning the acceptance 
of ES cells seems to be entering a new stage, 
while therapeutic cloning has already been 
socia l ly accepted and researched in some 
countries.
8      Conclusion
The pros and cons of therapeutic cloning 
have been socially discussed. As long as society 
demands and expects regenerative medicine and 
research in this area, protocols and systems for 
implementation that gain the acceptance and 
confidence of both sides must be established, 
based on social debate. As a candidate for such 
a system, the 2nd Policy- Oriented Research 
Group of the National Institute of Science and 
Technology Policy suggests a “social governance 
system of life science technology”[15], which 
comprehensively involves the participation of 
citizens and society, conducts risk management 
as well as the qualitative control of medical 
treatment and research, and protects subjects’ 
rights, through a structure in which a specialized 
intermediary agency is the core. An intermediary 
agenc y  i s  a n  orga n i zat ion  that  p l ays  a n  
intermediary role between scientific technology 
and society. As an example, the structure of a 
system for therapeutic cloning is depicted in 
Figure 4. Japan must consider the application of 
a governance system that secures confidence 
through the participation of citizens.
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Notes
*1 epigenet ic :  a  mode of  non - her i t able  
modification involved in the regulation of 
gene expression, etc., without changing 
the gene. The modification involves DNA 
methylation, histone protein modification, 
the higher-order structure of chromosomes, 
etc[8].
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